Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (65)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Andriole, V. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andriole, V. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 151-162
© 1999 The British Society for Antimicrobial Chemotherapy

The 1998 Garrod Lecture

Current and future antifungal therapy: new targets for antifungal agents

Vincent T. Andriole

Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06518, USA

Abstract

Invasive fungal infections are a major problem in immunocompromised patients. The recent expansion of antifungal drug research has occurred because there is a critical need for new antifungal agents to treat these life-threatening invasive infections. The overview of the development of antifungal therapy which is provided herein reflects the increased interest in this very special area of infectious diseases. Although we have newer, less toxic, antifungal agents that are available for clinical use, their clinical efficacy in some invasive fungal infections, such as aspergillosis and fusariosis, is not optimal. Thus, intense efforts in antifungal drug discovery are still needed to develop more promising and effective antifungal agents for use in the clinical arena.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
M Yordanov, P Dimitrova, S Patkar, S Falcocchio, E Xoxi, L Saso, and N Ivanovska
Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections
J. Med. Microbiol., July 1, 2005; 54(7): 647 - 653.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
H. S. Kim, E. H. Choi, J. Khan, E. Roilides, A. Francesconi, M. Kasai, T. Sein, R. L. Schaufele, K. Sakurai, C. G. Son, et al.
Expression of Genes Encoding Innate Host Defense Molecules in Normal Human Monocytes in Response to Candida albicans
Infect. Immun., June 1, 2005; 73(6): 3714 - 3724.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
R. J. Jurevic, M. Bai, R. B. Chadwick, T. C. White, and B. A. Dale
Single-Nucleotide Polymorphisms (SNPs) in Human {beta}-Defensin 1: High-Throughput SNP Assays and Association with Candida Carriage in Type I Diabetics and Nondiabetic Controls
J. Clin. Microbiol., January 1, 2003; 41(1): 90 - 96.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. M. Kuhn, T. George, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum
Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1773 - 1780.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. Tsuchimori, R. Hayashi, N. Kitamoto, K. Asai, T. Kitazaki, Y. Iizawa, K. Itoh, and K. Okonogi
In Vitro and In Vivo Antifungal Activities of TAK-456, a Novel Oral Triazole with a Broad Antifungal Spectrum
Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1388 - 1393.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Kamai, T. Harasaki, T. Fukuoka, S. Ohya, K. Uchida, H. Yamaguchi, and S. Kuwahara
In Vitro and In Vivo Activities of CS-758 (R-120758), a New Triazole Antifungal Agent
Antimicrob. Agents Chemother., February 1, 2002; 46(2): 367 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. G. Arathoon, E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable
Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases
Antimicrob. Agents Chemother., February 1, 2002; 46(2): 451 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
J. L. Santos and K. Shiozaki
Fungal Histidine Kinases
Sci. Signal., September 4, 2001; 2001(98): re1 - re1.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, P. B. Michelsen, and L. H. Bopp
Effects of Cytokines and Fluconazole on the Activity of Human Monocytes against Candida albicans
Antimicrob. Agents Chemother., January 1, 2001; 45(1): 96 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Roberts, K. Schock, S. Marino, and V. T. Andriole
Efficacies of Two New Antifungal Agents, the Triazole Ravuconazole and the Echinocandin LY-303366, in an Experimental Model of Invasive Aspergillosis
Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3381 - 3388.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Bigliardi, A. M. Bernuzzi, S. Corona, S. Gatti, M. Scaglia, and L. Sacchi
In Vitro Efficacy of Nikkomycin Z against the Human Isolate of the Microsporidian Species Encephalitozoon hellem
Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3012 - 3016.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.